Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03269409 · ClinicalTrials.gov registry record · Phase 1

Use of Adipose Derived Regenerative Cells in Bilateral Femoral Head Osteonecrosis

A Phase 1 study, sponsored by Mayo Clinic.

Terminated
Registry status
Phase 1
Development phase
8
Enrollment target

NCT03269409: Clinical Trial Phase 1 study, sponsored by Mayo Clinic.

NCT03269409 is a Phase 1 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03269409, a Phase 1 study, was terminated before completion, sponsored by Mayo Clinic.

TERMINATED
Registry status
Phase 1
Development phase
8 participants
Enrollment target

Study Summary

This randomized clinical trial aims to determine if cells from a patient's own adipose tissue is safe and capable of helping regenerate the femoral head in patients with osteonecrosis. The standard of care is known as hip decompression which simply removes dead tissue from the femoral head and creates a new cavity to be filled in by healthy bone. This trial will use hip decompression in one hip and hip decompression supplemented with adipose derived regenerative cells in patients with osteonecrosis in both of their hips.

Interventions

  • OTHER Lactated Ringers
  • DEVICE The Celution 800/GP System (Cytori Therapeutics)
  • BIOLOGICAL Adipose Derived Regenerative Cells (ADRC)

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2017-11-15
Est. Completion 2021-06-28
Phase Phase 1

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT03269409

The ClinicalTrials.gov registry entry for NCT03269409 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Lactated Ringers is the first listed.

NCT03269409 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03269409 about?

NCT03269409 is a clinical study titled "Use of Adipose Derived Regenerative Cells in Bilateral Femoral Head Osteonecrosis". This randomized clinical trial aims to determine if cells from a patient's own adipose tissue is safe and capable of helping regenerate the femoral head in patients with osteonecrosis. The standard of care is known as hip decompression which simply removes dead tissue from the femoral head and creat...

What is the current status of trial NCT03269409?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2017-11-15. Estimated completion is 2021-06-28.

What interventions are being tested in trial NCT03269409?

The interventions under investigation include: Lactated Ringers (OTHER), The Celution 800/GP System (Cytori Therapeutics) (DEVICE), Adipose Derived Regenerative Cells (ADRC) (BIOLOGICAL).

Who is sponsoring clinical trial NCT03269409?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.